All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

Human Papillomaviruses (HPV) are a group of DNA viruses commonly transmitted by sexual activity or other direct contact. They can infect the genital and anorectal areas, mouth, and throat of males and females.\[[@pone.0124499.ref001], [@pone.0124499.ref002]\] Over 40 types of HPV are reported, of which at least 13 are considered high-risk for leading to neoplasia in infected body sites. HPV infection is well-known for its association with the development of cervical cancer in women. To prevent this, HPV vaccination has been implemented for young women in many industrialized countries. \[[@pone.0124499.ref001], [@pone.0124499.ref003]\] There is also growing concern about the role of HPV in the increasing frequency of anal cancer in men who have sex with men (MSM) in developed countries. \[[@pone.0124499.ref004]--[@pone.0124499.ref006]\]

In Thailand, sex between men is common, with data from integrated analysis and advocacy across all surveys estimating that 2--15% of anatomical males have a history of sex with men. \[[@pone.0124499.ref007]\] There are many categories of gender roles, gender identities, sexual orientations, and behaviors within the broad classification referred to as MSM in Thailand. In general, they are comprised of three sub groups: gay men (GM) who self-identify as men and prefer insertive and/or receptive anal sex with other men, bisexual men (BM) who self-identify as men and engage in insertive and/or receptive anal sex with men and women, and transgender women (TGW) who are born as anatomical males (and who may or may not have undergone genital surgery), but who self-identify as women and prefer receptive anal sex with men.\[[@pone.0124499.ref008]--[@pone.0124499.ref010]\] These groups have different sexual practices that may pose different risks for acquisition of sexually transmitted infections (STIs), especially for HPV.

The prevalence of different infecting HPV types appears to vary both geographically and temporally. In 1990s, one HPV study among MSM in the USA reported the most common high-risk HPV types were 16, 18, 31 and 53 in descending frequency without any HPV vaccination available during that time. \[[@pone.0124499.ref011]\] A study of MSM in China reported in 2010 revealed that HPV type 16 was also the most frequent, followed by types 58 and 39. \[[@pone.0124499.ref012]\] In 2013, Phanuphak et al. also reported high rates of anal HPV infection of all types in MSM in Bangkok, Thailand, with frequencies among both HIV-positive (HIV+) of 85% and HIV-negative (HIV-) of 59%. \[[@pone.0124499.ref010]\] The most common high-risk HPV types were 16, 51 and 58. \[[@pone.0124499.ref010]\] These and most other similar studies were, however, in GM and/or BM subjects. \[[@pone.0124499.ref013]--[@pone.0124499.ref015]\] HPV types may also vary by risk group, but little is known about HPV frequency in TGW. Prior Thai studies focused on MSM in Bangkok or major tourist beach destinations such as Pattaya and Phuket. Equivalent data in northern Thailand has not been published. Right now in Thailand, an HPV vaccine is not included in the national immunization program either for boys or girls. Individuals who want to receive this vaccine need to pay for the whole course by themselves. The cost for this HPV vaccine in Thailand is around US \$200--250 per person.

To provide a basis for future policymaking on the use of HPV vaccines in public immunization programs for high-risk individuals, we studied the prevalence of anal HPV, its infecting types, and risk factors for its acquisition among three subgroups of MSM in northern Thailand.

Methods {#sec006}
=======

Study population and venue {#sec007}
--------------------------

The PIMAN Center is a clinic located in Chiang Mai city, northern Thailand, and has provided voluntary counseling and testing and STI treatment services for MSM since 2007. The clinic is operated by the Research Institute for Health Sciences (RIHES) of Chiang Mai University, and participates in a range of multi-site epidemiological and clinical studies in MSM populations, such as pre-exposure chemoprophylaxis for HIV prevention (e.g., the iPrEx trial) and rectal microbicides (e.g., the MTN-017 study). About 400 MSM clients who attended the PIMAN Center, between July 2012- January 2013, were approached about their interest in participating in this HPV study. The study inclusion criteria were self-identification as GM, BM, or TGW, age 18 years or older, and a history of anal receptive sexual intercourse in the preceding 6 months. Of those clients, there were 200 MSM who voluntarily provided informed consent to be enrolled in the study.

Data and sample collection {#sec008}
--------------------------

Data were collected using a computer-assisted self-interview (CASI) program, and then by trained study staff in a private room. Each participant was assigned a unique identification code to anonymously link questionnaire responses and biologic specimens. Data collected via CASI or by staff included socio-demographic characteristics, substance use history, gender identity, history of HIV testing, history of prior STIs, and various sexual behaviors.

HIV testing {#sec009}
-----------

The HIV status of study participants who reported being HIV+ from testing elsewhere were classified as such only if they provided written medical documentation of their status. Participants with undocumented, unknown, or prior HIV- status were provided with counseling and HIV testing, if consenting, to HIV testing; those declining HIV testing were classified as HIV-unknown (HIV^unk^).

HIV infection was determined by rapid test with the Alere Determine HIV 1/2 (Alere Medical Co, Ltd., Chiba, Japan), with confirmation of positives by enzyme-linked immunosorbent assay with the AxSYM HIV 1/2 gO (ABBOTT, Wiesbaden, Germany). For discordant results on these two tests, gelatin particle agglutination assay with the SERODIA---HIV (Fujirebio Inc., Tokyo, Japan) was used for final determination.

Specimen collection {#sec010}
-------------------

Anal samples for HPV DNA detection and genotyping were collected by physicians. A saline-moistened nylon swab was introduced into the anal canal to 5 cm depth. The swab was rotated in a circular motion for one minute, while gentle pressure was applied against the walls of the anal canal. The swab sample was placed immediately in thinPrep PreserveCyt solution (Hologic, Boxborough, MA, USA), and transported to the laboratory for cytology and HPV DNA testing.

HPV detection and genotyping {#sec011}
----------------------------

DNA was extracted from the anal specimens using the DNeasy Blood & Tissue Kit (Qiagen, Hilden, Germany). Briefly, the cells were preserved in PreserveCyt solution and were pelleted by centrifugation at 1000 *g* at 20°C for 15 minutes. The cells were washed once with 1 x Dulbecco's Phosphate-Buffered Saline (Invitrogen, Carlsbad, CA, USA), then subjected to DNA extraction according to the protocol provided by the manufacturer. The purified DNA was stored at -20°C until use.

Nested polymerase chain reaction (PCR) assays determined the presence of HPV in the 10 μl DNA extracts from the anal specimens, using consensus PGMY09/11/HMB01 HPV L1 primers in the first-round. These were followed by the GP5+/6+ primers in the second-round. \[[@pone.0124499.ref016]\] Co-amplification of the human β-globin gene in the first-round PCR was used as a positive control; samples that were negative for both HPV DNA and β-globin were considered inadequate, whereas those negative for GP5+/6+ and positive for β-globin were regarded as HPV DNA negative.

Samples that were positive for HPV using this approach were further analyzed using a line-blot assay ([Linear Array]{.smallcaps} HPV Genotyping Test \[LA-HPV\]; Roche Diagnostics GmBH, Mannheim, Germany), which detects 13 high-risk HPV genotypes (types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68), and 24 low-risk genotypes (6, 11, 26, 40, 42, 53, 54, 55, 61, 62, 64, 66, 67, 69, 70, 71, 72, 73, 81, 82, 83, 84, IS39, and CP6108). Positive and negative controls used for the LA-HPV were those supplied with the kit. The probe for HPV type 52 is a mixed one that cross-reacts with types 33, 35, and 58; thus, identifications of type 52 reported here include only those without concurrent presence of the latter three types. Samples that tested positive by HPV DNA PCR but without a positive band on the LA-HPV strip were classified as type undetermined.

Vaccine coverage {#sec012}
----------------

The HPV types identified were tabulated according to their coverage by the bivalent (16/18) and quadrivalent (16/18/6/11) commercially available vaccines, as well as by the 7-valent (16/18/31/33/45/52/58), and 9-valent (16/18/31/33/45/52/58/6/11) investigational ones. An HPV+ participant was considered "covered" by a vaccine if ≥1 of the type(s) identified to infect that participant was among a vaccine's component antigens. Thus, our estimates are for "partial" coverage only, because a vaccine's antigens may only correspond to some---but not all---of the HPV infections in a participant co-infected with multiple types.

Statistical analysis {#sec013}
--------------------

The data were analyzed statistically using Stata/IC for Windows, Version 10.0 (StataCorp LP, College Station, TX, USA). Statistical significance for categorical data was determined by Pearson's Chi-square test. Paired proportions were compared by McNemar\'s test. For bivariate data, odds ratios (OR) and 95% confidence intervals (95% CI) were calculated and statistical significance determined by Chi-square (χ^2^) test.

Potential demographic, sexual, behavioral, and other risk factors or predictors for the assessed outcome of HPV infection were analyzed by multivariate logistic regression. The variable-selection process for the multivariate model began with bivariate analysis of each variable, for which those with p values of \<0.25 were candidates for the multivariate analysis. When specific analytical data cells had counts of zero, exact logistic regression was used. Forward selection was then applied by starting with a simple model and adding terms sequentially until further additions did not significantly improve the fit. Covariates were removed from the model if non-significant and not confounders. \[[@pone.0124499.ref017]\]

Ethics {#sec014}
------

Study protocols, questionnaires, and written informed consent were approved by the Ethics Committee of the Research Institute for Health Sciences, Chiang Mai University. PIMAN Center attendees were provided with information about the study and invited to participate. Only those who voluntarily provided written informed consent were enrolled. Participants were informed of their study test results for HIV and HPV, followed by appropriate counseling and treatment. Any STIs diagnosed in the course of the study were treated by the study team at the PIMAN Center, and/or referred to appropriate clinical facilities elsewhere for further treatment. Publication of the study data is in accordance with the community standards and approved by the ethics committee.

Results {#sec015}
=======

Participant characteristics {#sec016}
---------------------------

The study population comprised equal numbers of GM (85, 42.5%) and TGW (85, 42.5%), while 30 (15%) BM constituted the remainder ([Table 1](#pone.0124499.t001){ref-type="table"}). GM were twice as likely to have any university education (62%) than either BM (30%) or TGW (28%). The majority (55%) of the participants was between 20 and 29 years old (overall age range 18--54 years) and 43% had a university degree.

10.1371/journal.pone.0124499.t001

###### Demographic characteristics of age, education, occupation, and nationality, by gender-identity of MSM subjects in Chiang Mai, Thailand, 2012--2013.

![](pone.0124499.t001){#pone.0124499.t001g}

  Demographic Variables                Gender identity   Totals                                          
  ------------------------------------ ----------------- --------------- --------------- --------------- --------------------------------------
  **Age in years, N (%)**                                                                                
   \< 20                               8 (9)             4 (13)          15 (18)         27 (14)         χ^2^ ~(6)~ = 12.6, ***p = 0*.*049***
   20--29                              40 (47)           19 (63)         51 (60)         110 (55)        
   30--39                              27 (32)           7 (23)          14 (16)         48 (24)         
   ≥ 40                                10 (12)           0               5 (6)           15 (8)          
  *Mean / Median*                      *29*.*5 / 27*     *25*.*2 / 24*   *25*.*6 / 23*   *27*.*2 / 25*   
  *Min*.*-Max*.                        *18--54*          *18--36*        *18--48*        *18--54*        
  **Highest education level, N(%)**                                                                      
   None                                3 (4)             4 (13)          5 (6)           12 (6)          χ^2^ ~(8)~ = 30.9, ***p = 0*.*000***
   Any primary (1 to ≤6 grades)        0                 1 (3)           0               1 (1)           
   Any secondary (1 to ≤6 grades)      13 (15)           7 (23)          22 (26)         42 (21)         
   Any vocational (after 2° grade 3)   16 (19)           9 (30)          34 (40)         59 (30)         
   Any university                      53 (62)           9 (30)          24 (28)         86 (43)         
  **Main occupation, N(%)**                                                                              
   Student                             23 (27)           5 (17)          32 (38)         60 (30)         χ^2^ ~(4)~ = 15.8, ***p = 0*.*003***
   Employed                            58 (68)           17 (57)         43 (51)         118 (59)        
   Unemployed                          4 (5)             8 (27)          10 (12)         22 (11)         
  **Nationality, N(%)**                                                                                  
   Thai                                84 (99)           29 (97)         85 (100)        198 (99)        χ^2^ ~(2)~ = 2.5, *p = 0*.*280*, NS
   Thai ethnic minority                1 (1)             1 (3)           0               2 (1)           

Sexual behavior and history {#sec017}
---------------------------

Five variables of sexual behavior stood out for statistically-significant differences between the gender-identity groups ([Table 2](#pone.0124499.t002){ref-type="table"}). TGW reported a higher frequency of exclusively receptive anal sex than both the GM and BM (p \< 0.001). GM reported less-frequent sexual intercourse with men or women than the BM and TGW groups (p \< 0.001). GM consumed alcohol before sex less frequently than BM and TGW (p \< 0.01). BM received something of value in exchange for sex more often than GM or TGW (p \< 0.0001). TGW reported lower frequency than GM and BM of penile symptoms suggestive of STIs (p \<0.001).

10.1371/journal.pone.0124499.t002

###### Frequency of sexual and other behaviors, by gender-identity of MSM subjects in Chiang Mai, Thailand, 2012--2013.

![](pone.0124499.t002){#pone.0124499.t002g}

  Sexual Behavior Variables                                                                         Gender identity   Totals                                          
  ------------------------------------------------------------------------------------------------- ----------------- -------------- ------------------ ------------- ----------------------------------------
  **Regular partner status, N(%)**                                                                                                                                    χ^2^ ~(2)~ = 3.4, *p = 0*.*187*, NS
   No                                                                                               61 (72)           26 (87)        68 (80)            155 (78)      
   Yes                                                                                              24 (28)           4 (13)         17 (20)            45 (22)       
  **Sexual role, N(%)**                                                                                                                                               χ^2^ ~(4)~ = 69.0, ***p = 0*.*000***
   Insertive only                                                                                   0                 3 (10)         1 (1)              4 (2)         
   Receptive only                                                                                   40 (47)           5 (17)         76 (89)            121 (60)      
   Both insertive and receptive                                                                     45 (53)           22 (73)        8 (9)              75 (38)       
  **Last 6 months, anal intercourse with sex partner(s), N(%)**                                                                                                       
   None                                                                                             1 (1)             0              2 (2)              3 (2)         χ^2^ ~(6)~ = 4.8, *p = 0*.*310*, NS
   Yes                                                                                              78 (95)           24 (89)        80 (95)            182 (94)      
   No sex at all                                                                                    3 (4)             3 (11)         2 (2)              8 (4)         
   Declined to answer [\*](#t002fn001){ref-type="table-fn"}                                         3                 3              1                  7             
     **If yes, use condom all the time last 6 months**                                                                                                                χ^2^ ~(2)~ = 4.5, *p = 0*.*107*, NS
     Yes                                                                                            38 (49)           7 (29)         28 (35)            73 (40)       
     No                                                                                             40 (51)           17 (71)        52 (65)            109 (60)      
  **Sexual intercourse frequency with men or women, N(%)**                                                                                                            χ^2^ ~(6)~ = 26.9, ***p = 0*.*000***
   Everyday                                                                                         0                 4 (13)         8 (9)              12 (6)        
   3--4 times per week                                                                              12 (14)           12 (40)        23 (27)            47 (24)       
   1--2 times per week                                                                              27 (32)           6 (20)         30 (35)            63 (32)       
   One per month or less                                                                            46 (54)           8 (27)         24 (28)            78 (39)       
  **Drink alcohol before sex with BM, GM, or TGW, N(%)**                                                                                                              χ^2^ ~(6)~ = 17.8, ***p = 0*.*007***
   Every time                                                                                       1 (1)             6 (20)         5 (6)              12 (6)        
   Almost every time                                                                                8 (9)             4 (13)         13 (15)            25 (12)       
   Sometimes                                                                                        45 (53)           13 (43)        47 (55)            105 (52)      
   Never                                                                                            31 (36)           7 (23)         20 (24)            58 (29)       
  **Ever give money, gifts or valuables in exchange for sex with BM, GM or TGW, N(%)**                                                                                χ^2^ ~(2)~ = 2.9, *p = 0*.*238*, NS
   No                                                                                               62 (73)           24 (80)        71 (84)            157 (78)      
   Yes                                                                                              23 (27)           6 (20)         14 (16)            43 (22)       
     **If yes, when was the last time**                                                                                                                               χ^2^ ~(2)~ = 2.1, *p = 0*.*354*, NS
     1 year or less                                                                                 17 (74)           5 (83)         13 (93)            35 (81)       
     More than 1 year                                                                               6 (26)            1 (17)         1 (7)              8 (19)        
  **Ever receive money, gifts or valuables in exchange for sex, N(%)**                                                                                                χ^2^ ~(2)~ = 20.7, ***p = 0*.*000***
   Never                                                                                            71 (84)           12 (40)        60 (71)            143 (72)      
   Ever                                                                                             14 (16)           18 (60)        25 (29)            57 (28)       
     **If ever last time**                                                                                                                                            χ^2^ ~(2)~ = 0.9, *p = 0*.*642*, NS
     1 year or less                                                                                 10 (71)           15 (83)        18 (72)            43 (75)       
     More than 1 year                                                                               4 (29)            3 (17)         7 (28)             14 (25)       
  **Ever circumcised?, N(%)**                                                                                                                                         χ^2^ ~(2)~ = 0.7, *p = 0*.*705*, NS
   Yes                                                                                              4 (5)             1 (3)          2 (2)              7 (4)         
   No                                                                                               81 (95)           29 (97)        83 (98)            193 (96)      
  **Number of total sex partner(s) last 6 months, N(%)**                                                                                                              χ^2^ ~(6)~ = 11.0, *p = 0*.*088*, NS
   None                                                                                             3 (4)             3 (11)         2 (2)              8 (4)         
   1                                                                                                20 (24)           3 (11)         19 (23)            42 (22)       
   2--4                                                                                             34 (41)           6 (22)         31 (37)            71 (37)       
   5 or more                                                                                        25 (30)           15 (56)        32 (38)            72 (37)       
   Declined to answer [\*](#t002fn001){ref-type="table-fn"}                                         3                 3              1                  7             
  *Mean / Median*                                                                                   *4*.*6 / 3*       *14*.*2 / 7*   *10*.*8 / 3*.*5*   *8*.*6 / 3*   
  *Min*.*-Max*.                                                                                     *0--45*           *0--103*       *0--300*           *0--300*      
  **Ever have unusual fluid, urinary irritation, ulcer, or rash on penis in last 6 months, N(%)**                                                                     χ^2^ ~(2)~ = 16.1, ***p = 0*.*000***
   Yes                                                                                              17 (20)           9 (30)         3 (4)              29 (14)       
   No                                                                                               68 (80)           21 (70)        82 (96)            171 (86)      
     **If yes, see doctor and get diagnosis**                                                                                                                         χ^2^ ~(2)~ = 1.4, *p = \> 0*.*507*, NS
     Yes                                                                                            9 (53)            3 (33)         2 (67)             14 (48)       
     No                                                                                             8 (47)            6 (67)         1 (33)             15 (52)       

**\*** Not included in testing for statistical significance.

HIV and HPV prevalence and co-infections {#sec018}
----------------------------------------

Of the 200 participants, 49 (24.5%) were HIV+, 122 (61.0%) HIV-, and 29 (14.5%) HIV^unk^ ([Table 3](#pone.0124499.t003){ref-type="table"}). HPV infection with any type was found in 157 (79.7%) of 197 with adequate anal-swab samples. Among the HIV+ subjects, all 48 (100%) with adequate specimens were found on Linear Array HPV assay to be infected with one or more HPV types, which was significantly higher than the 70% rate (84 of 120) among HIV- subjects (*p* \<0.01).

10.1371/journal.pone.0124499.t003

###### HPV infections and co-infections by HIV infection status of MSM subjects studied in Chiang Mai, Thailand, 2012--2013.

![](pone.0124499.t003){#pone.0124499.t003g}

  Variables                                                                HIV Infection   Totals                                    
  ------------------------------------------------------------------------ --------------- ------------- ------------- ------------- --------------------------------------
  **HPV DNA by PCR, N(%)**                                                                                                           χ^2^ ~(1)~ = 12.3, ***p = 0*.*000***
   HPV+                                                                    48 (100)        94 (78)       25 (86)       167 (85)      
   HPV-                                                                    0               26 (22)       4 (14)        30 (15)       
   Inadequate specimen[\*](#t003fn001){ref-type="table-fn"}                1               2             0             3             
  **HPV DNA by linear array, N(%)**                                                                                                  χ^2^ ~(1)~ = 15.0, ***p = 0*.*000***
   HPV+                                                                    48 (100)        84 (74)       25 (86)       157 (83)      
   HPV-                                                                    0               29 (26)       4 (14)        33 (17)       
   Undetermined type, Not specified[\*](#t003fn001){ref-type="table-fn"}   0               7             0             7             
  **Number HPV co-infection, N(%)**                                                                                                  χ^2^ ~(5)~ = 32.2, ***p = 0*.*000***
   None                                                                    0               36 (30)       4 (14)        40 (20)       
   1                                                                       2 (4)           20 (17)       6 (21)        28 (14)       
   2                                                                       5 (10)          15 (12)       5 (17)        25 (13)       
   3--5                                                                    25 (52)         34 (28)       5 (17)        64 (32)       
   6--8                                                                    14 (29)         13 (11)       7 (24)        34 (17)       
   ≥ 9                                                                     2 (4)           2 (2)         2 (7)         6 (3)         
  *Mean / Median*                                                          *4*.*8 / 4*     *3*.*4 / 3*   *4*.*1 / 3*   *3*.*9 / 4*   
  *Min*.*-Max*.                                                            *1--12*         *1--10*       *1--9*        *1--12*       
  **Frequency of low and high risk HPV types, N(%)**                                                                                 χ^2^ ~(3)~ = 25.0, ***p = 0*.*000***
   None                                                                    0               36 (30)       4 (14)        40 (20)       
   Only low risk(LR) type(s)                                               3 (6)           19 (16)       3 (10)        25 (13)       
   Only high risk(HR) type(s)                                              5 (10)          8 (7)         4 (14)        17 (9)        
   Both LR and HR type(s)                                                  40 (83)         57 (48)       18 (62)       115 (58)      
  **Number of high-risk HPV co-infection(s), N(%)**                                                                                  χ^2^ ~(4)~ = 28.8, ***p = 0*.*000***
   None                                                                    3 (6)           55 (46)       7 (24)        65 (33)       
   1                                                                       11 (23)         20 (17)       12 (41)       43 (22)       
   2                                                                       12 (25)         22 (18)       1 (3)         35 (18)       
   3--5                                                                    18 (38)         22 (18)       8 (28)        48 (24)       
   6--8                                                                    4 (8)           1 (1)         1 (3)         6 (3)         
  *Mean / Median*                                                          *2*.*8 / 2*     *2*.*2 / 2*   *2*.*2 / 1*   *2*.*4 / 2*   
  *Min*.*-Max*.                                                            *1--7*          *1--7*        *1--6*        *1--7*        

**\*** Not included in testing for statistical significance.

Infection with multiple HPV types was common ([Table 3](#pone.0124499.t003){ref-type="table"}): 13% (25/197) were co-infected with two types, 32% (64) 3-to-5 types, 17% (37) 6-to-8 different types, and 3% (6) ≥9 types. The mean number of HPV types was 4.8 among HIV+ participants (range 1 to 12), compared to 3.4 (range 1--10) in the HIV- (*p* \< 0.001)

HPV infection with any of the 13 high-risk types was found in 132 of 197 (67.0%) ([Table 3](#pone.0124499.t003){ref-type="table"}). Co-infections with ≥1 high-risk types among HIV+ was 94% (45 of 48), and in HIV- 54% (65 of 120) (*p \<* 0.0001).

HPV types and vaccine coverage {#sec019}
------------------------------

The most common high-risk HPV types were 16 (27%), 58 (23%), 51(18%), and 39 (14%) ([Fig 1](#pone.0124499.g001){ref-type="fig"}). Infection by type 16 was more common in HIV+ (40%, 19/48), versus 22% (26/120) in HIV- (*p* \< 0.02). Increasing vaccine valences from 2, to 4, to 7, and to 9 increased the percentage of participants who were infected with at least one HPV type covered in a vaccine from 35.5% (70/197), to 48.2% (95), to 56.4% (111), and to 64.0% (126), respectively ([Table 4](#pone.0124499.t004){ref-type="table"}). HPV vaccine coverage for either HIV+ or HIV- increased steadily as valency increased from 2 to 4, to 7, and to 9 ([Table 5](#pone.0124499.t005){ref-type="table"}).

![Prevalence of high-risk HPV types, by HIV status, ranked from left to right by decreasing percentage among total participants.](pone.0124499.g001){#pone.0124499.g001}

10.1371/journal.pone.0124499.t004

###### Coverage by commercial[^a^](#t004fn001){ref-type="table-fn"},[^b^](#t004fn002){ref-type="table-fn"} and investigational[^c^](#t004fn003){ref-type="table-fn"},[^d^](#t004fn004){ref-type="table-fn"} HPV vaccines of ≥1 HPV infecting type(s), by gender identity of MSM subjects in Chiang Mai, Thailand, 2012--2013.

![](pone.0124499.t004){#pone.0124499.t004g}

                                No. of participant / Total cases (%)   Increased percentage coverage above 2-valent (95% CI)   Ratio to 2-valent (95% CI)   Statistic, *p-value*
  ----------------------------- -------------------------------------- ------------------------------------------------------- ---------------------------- ---------------------------------------
  **Gay Men, N(%)**                                                                                                                                         
   2-valent                     33 / 85 (38.8)                         Ref.                                                                                 
   4-valent                     45 / 85 (52.9)                         +14.1 (5.5--22.7)                                       1.4 (1.1--1.6)               χ^2^ ~(1)~ = 12.0, ***p = 0*.*0005***
   7-valent                     54 / 85 (63.5)                         +24.7 (14.4--35.1)                                      1.6 (1.3--2.0)               χ^2^ ~(1)~ = 21.0, ***p = 0*.*000***
   9-valent                     61 / 85 (71.8)                         +32.9 (21.8--44.1)                                      1.9 (1.5--2.3)               χ^2^ ~(1)~ = 28.0, ***p = 0*.*000***
  **Bisexual Men, N(%)**                                                                                                                                    
   2-valent                     7 / 29 (24.1)                          Ref.                                                                                 
   4-valent                     10 / 29 (34.5)                         +10.3 (-4.2--24.9)                                      1.4 (1.0--2.1)               χ^2^ ~(1)~ = 3.0, *p = 0*.*083*, *NS*
   7-valent                     8 / 29 (27.6)                          +3.5 (-6.6--13.5)                                       1.1 (0.9--1.5)               χ^2^ ~(1)~ = 1.0, *p = 0*.*317*, *NS*
   9-valent                     11 / 29 (37.9)                         +13.8 (-2.2--29.8)                                      1.6 (1.0--2.5)               χ^2^ ~(1)~ = 4.0, ***p = 0*.*046***
  **Transgender Women, N(%)**                                                                                                                               
   2-valent                     30 / 83 (36.1)                         Ref.                                                                                 
   4-valent                     40 / 83 (48.2)                         +12.1 (3.8--20.3)                                       1.3 (1.1--1.6)               χ^2^ ~(1)~ = 10.0, ***p = 0*.*002***
   7-valent                     49 / 83 (59.0)                         +22.9 (12.7--33.1)                                      1.6 (1.3--2.0)               χ^2^ ~(1)~ = 19.0, ***p = 0*.*000***
   9-valent                     54 / 83 (65.1)                         +28.9 (18.0--39.9)                                      1.8 (1.4--2.3)               χ^2^ ~(1)~ = 24.0, ***p = 0*.*000***
  **All participant, N(%)**                                                                                                                                 
   2-valent                     70 / 197 (35.5)                        Ref.                                                                                 
   4-valent                     95 / 197 (48.2)                        +12.7 (7.5--17.8)                                       1.4 (1.2--1.5)               χ^2^ ~(1)~ = 25.0, ***p = 0*.*000***
   7-valent                     111 / 197 (56.4)                       +20.8 (14.6--27.0)                                      1.6 (1.4--1.8)               χ^2^ ~(1)~ = 41.0, ***p = 0*.*000***
   9-valent                     126 / 197 (64.0)                       +28.4 (21.6--35.2)                                      1.8 (1.5--2.1)               χ^2^ ~(1)~ = 56.0, ***p = 0*.*000***

^***a***^ 2--valent coverage: number infected with ≥1 HPV type(s) 16 and/or 18

^***b***^ 4--valent coverage: number infected with ≥1 HPV type(s) 16, 18, 6, and/or 11

^***c***^ 7--valent coverage: number infected with ≥1 HPV type(s) 16, 18, 31, 33, 45, 52, and/or 58

^***d***^ 9--valent coverage: number infected with ≥1 HPV type(s) 16, 18, 31, 33, 45, 52, 58, 6, and/or 58).

10.1371/journal.pone.0124499.t005

###### Coverage by commercial[^a^](#t005fn001){ref-type="table-fn"},[^b^](#t005fn002){ref-type="table-fn"} and investigational[^c^](#t005fn003){ref-type="table-fn"},[^d^](#t005fn004){ref-type="table-fn"} HPV vaccines of ≥1 HPV infecting type(s), by HIV status of MSM subjects in Chiang Mai, Thailand, 2012--2013.
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                                No. of participant / Total cases (%)   Increased percentage coverage above 2-valent (95% CI)   Ratio to 2-valent (95% CI)   Statistic, *p-value*
  ----------------------------- -------------------------------------- ------------------------------------------------------- ---------------------------- ---------------------------------------
  **HIV+, N(%)**                                                                                                                                            
   2-valent                     28 / 48 (58.3)                         Ref.                                                                                 
   4-valent                     34 / 48 (70.8)                         +12.5 (1.1--23.9)                                       1.2 (1.0--1.4)               χ^2^ ~(1)~ = 6.0, ***p = 0*.*014***
   7-valent                     39 / 48 (81.3)                         +22.9 (8.9--36.9)                                       1.4 (1.1--1.7)               χ^2^ ~(1)~ = 11.0, ***p = 0*.*001***
   9-valent                     42 / 48 (87.5)                         +29.2 (14.2--44.1)                                      1.5 (1.2--1.9)               χ^2^ ~(1)~ = 14.0, ***p = 0*.*0002***
  **HIV-, N(%)**                                                                                                                                            
   2-valent                     32 / 120 (26.7)                        Ref.                                                                                 
   4-valent                     47 / 120 (39.2)                        +12.5 (5.8--19.3)                                       1.5 (1.2--1.8)               χ^2^ ~(1)~ = 15.0 ***p = 0*.*0001***
   7-valent                     55 / 120 (45.8)                        +19.2 (11.3--27.0)                                      1.7 (1.4--2.2)               χ^2^ ~(1)~ = 23.0, ***p = 0*.*000***
   9-valent                     65 / 120 (54.2)                        +27.5 (18.7--36.3)                                      2.0 (1.6--2.6)               χ^2^ ~(1)~ = 33.0, ***p = 0*.*000***
  **HIV** ^**unk**^, **N(%)**                                                                                                                               
   2-valent                     10 / 29 (34.5)                         Ref.                                                                                 
   4-valent                     14 / 29 (48.3)                         +13.8 (-2.2--29.8)                                      1.4 (1.1--2.0)               χ^2^ ~(1)~ = 4.0, ***p = 0*.*046***
   7-valent                     17 / 29 (58.6)                         +24.1 (5.1--43.2)                                       1.7 (1.1--2.5)               χ^2^ ~(1)~ = 7.0, ***p = 0*.*008***
   9-valent                     19 / 29 (65.5)                         +31.0 (10.8--51.3)                                      1.9 (1.2--2.9)               χ^2^ ~(1)~ = 9.0, ***p = 0*.*003***
  **All participant, N(%)**                                                                                                                                 
   2-valent                     70 / 197 (35.5)                        Ref.                                                                                 
   4-valent                     95 / 197 (48.2)                        +12.7 (7.5--17.8)                                       1.4 (1.2--1.5)               χ^2^ ~(1)~ = 25.0, ***p = 0*.*000***
   7-valent                     111 / 197 (56.4)                       +20.8 (14.6--27.0)                                      1.6 (1.4--1.8)               χ^2^ ~(1)~ = 41.0, ***p = 0*.*000***
   9-valent                     126 / 197 (64.0)                       +28.4 (21.6--35.2)                                      1.8 (1.5--2.1)               χ^2^ ~(1)~ = 56.0, ***p = 0*.*000***

^***a***^ 2--valent coverage: number infected with ≥1 HPV type(s) 16 and/or 18

^***b***^ 4--valent coverage: number infected with ≥1 HPV type(s) 16, 18, 6, and/or 11

^***c***^ 7--valent coverage: number infected with ≥1 HPV type(s) 16, 18, 31, 33, 45, 52, and/or 58

^***d***^ 9--valent coverage: number infected with ≥1 HPV type(s) 16, 18, 31, 33, 45, 52, 58, 6, and/or 58.

Determinants of anal HPV infection {#sec020}
----------------------------------

On univariate analysis, the odds ratio (OR) for anal HPV infection with any type virus among GM was 9.0 (95% CI 2.97--28.03, *p* \<0.001), and among TGW 4.5 (95% CI 1.63--12.26, *p* = 0.001), compared to BM as the referents ([Table 6](#pone.0124499.t006){ref-type="table"}). The adjusted odd ratio (AOR) by exact logistic regression for GM was 5.3 (95% CI 1.2--25.7, *p* = 0.027), compared to BM as referents.

10.1371/journal.pone.0124499.t006

###### Crude and adjusted Odds ratios by bivariate and exact logistic regression for any HPV positivity by demographic, behavioral, and sexual risk factors of MSM in Chiang Mai, Thailand.
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  Characteristics                                                                        No. cases   Bivariate analysis   Exact logistic regression analysis [^a^](#t006fn001){ref-type="table-fn"}                                                       
  -------------------------------------------------------------------------------------- ----------- -------------------- --------------------------------------------------------------------------- ------------ --------------- -------- ------------- ----------------
  **Gender identity**                                                                                                                                                                                                                                     
   Bisexual men                                                                          29          14 (48)              *Ref*.                                                                                                   *Ref*.                 
   Gay men                                                                               85          76 (89)              9.0                                                                         3.0--28.0    ***0*.*000***   5.3      1.2--25.7     ***0*.*027***
   Transgender women                                                                     83          67 (81)              4.5                                                                         1.6--12.3    ***0*.*001***   4.0      1.0--16.8     *0*.*055*
  **HIV status**                                                                                                                                                                                                                                          
   Negative                                                                              120         84 (70)              *Ref*.                                                                                                   *Ref*.                 
   Positive                                                                              48          48 (100)             41.9                                                                        2.5--698.0   ***0*.*001***   20.3     3.3 - +inf.   ***0*.*0002***
   Unknown                                                                               29          25 (86)              2.7                                                                         0.8--11.3    *0*.*078*       3.3      0.9--16.9     *0*.*080*
  **Age in years**                                                                                                                                                                                                                                        
   \< 20                                                                                 27          22 (82)              *Ref*.                                                                                                                          
   20--29                                                                                108         84 (78)              0.8                                                                         0.2--2.5     *0*.*675*                              
   30--39                                                                                47          37 (79)              0.8                                                                         0.2--3.2     *0*.*776*                              
   40 or more                                                                            15          14 (93)              3.2                                                                         0.3--161.0   *0*.*293*                              
  **Sexual role**                                                                                                                                                                                                                                         
   Insertive only & both                                                                 78          58 (74)              *Ref*.                                                                                                                          
   Receptive only                                                                        119         99 (83)              1.7                                                                         0.8--3.6     *0*.*132*                              
  **Ever used hormones**                                                                                                                                                                                                                                  
   Never                                                                                 98          76 (78)              *Ref*.                                                                                                                          
   Ever                                                                                  99          81 (82)              1.3                                                                         0.6--2.8     *0*.*457*                              
  **Alcohol consumption**                                                                                                                                                                                                                                 
   Never                                                                                 18          15 (83)              *Ref*.                                                                                                                          
   Ever                                                                                  179         142 (79)             0.8                                                                         0.1--2.9     *0*.*687*                              
  **Frequency of sexual intercourse with BM, GM or TGM**                                                                                                                                                                                                  
   1--2 times/week or less                                                               140         111 (79)             *Ref*.                                                                                                                          
   3--4 times/week or more                                                               57          46 (81)              1.1                                                                         0.5--2.6     *0*.*823*                              
  **Drank alcohol before having sex with BM, GM or TGW**                                                                                                                                                                                                  
   Never / sometime                                                                      162         135 (83)             *Ref*.                                                                                                   *Ref*.                 
   Almost every time / Every time                                                        35          22 (63)              0.3                                                                         0.1--0.8     ***0*.*006***   0.4      0.1--1.3      *0*.*127*
  **BM, GM or TGW partner drank alcohol before having sex with you**                                                                                                                                                                                      
   Never / sometime                                                                      164         134 (82)             *Ref*.                                                                                                                          
   Almost every time/ Every time                                                         33          23 (70)              0.5                                                                         0.2--1.4     *0*.*118*                              
  **Ever received money, gifts or valuables in exchange for sex**                                                                                                                                                                                         
   Never                                                                                 141         114 (81)             *Ref*.                                                                                                                          
   Ever                                                                                  56          43 (77)              0.8                                                                         0.4--1.8     *0*.*522*                              
  **Ever had any fluid, irritating urinary symptom, ulcer, or rash on your penis**                                                                                                                                                                        
   No                                                                                    169         135 (80)             *Ref*.                                                                                                                          
   Yes                                                                                   28          22 (79)              0.9                                                                         0.3--3.0     *0*.*873*                              
  **Total sex partner(s) last 6 months**                                                                                                                                                                                                                  
   0--1                                                                                  49          35 (71)              *Ref*.                                                                                                   *Ref*.                 
   2 or more                                                                             141         117 (83)             2.0                                                                         0.8--4.4     *0*.*082*       2.2      0.8--6.0      *0*.*157*
  **Number of female sex partner(s) last 6 months**                                                                                                                                                                                                       
   0--1                                                                                  172         143 (83)             *Ref*.                                                                                                   *Ref*.                 
   2 or more                                                                             16          7 (44)               0.2                                                                         0--0.5       ***0*.*000***   0.3      0.0--2.4      *0*.*368*
  **Use condom all the time last 6 months with sex partner(s)**                                                                                                                                                                                           
   No sex partner / No anal sex                                                          10          7 (70)               *Ref*.                                                                                                                          
   Yes                                                                                   73          60 (82)              2.0                                                                         0.3--10.1    *0*.*359*                              
   No                                                                                    107         85 (79)              1.7                                                                         0.2--8.0     *0*.*486*                              
  **Use condom all the time last 6 months with** [**regular**]{.ul} **sex partner(s)**                                                                                                                                                                    
   No sex partner / No anal sex                                                          74          56 (76)              *Ref*.                                                                                                                          
   Yes                                                                                   46          38 (83)              1.5                                                                         0.6--4.5     *0*.*370*                              
   No                                                                                    73          59 (81)              1.4                                                                         0.6--3.2     *0*.*450*                              
  **Use condom all the time last 6 months with** [**casual**]{.ul} **sex partner(s)**                                                                                                                                                                     
   No sex partner / No anal sex                                                          47          36 (77)              *Ref*.                                                                                                                          
   Yes                                                                                   75          61 (81)              1.3                                                                         0.5--3.5     *0*.*528*                              
   No                                                                                    72          59 (82)              1.4                                                                         0.5--3.8     *0*.*477*                              

^**a**^ Exact logistic regression used for these estimates due to zero cell counts

^**b**^ AOR = adjusted odd ratio. All measures adjusted for drinking alcohol before having sex, number of total sex partner(s) in last 6 months and number of female sex partner(s) in last 6 months

OR = crude odds ratio

Inf. = infinity

*Ref*. = Reference value.

For HIV+ participants, the any-type bivariate OR was 41.9 (95% CI 2.54--698.02, *p* = 0.001), compared to the HIV- as the referent. The AOR for the HIV+ was 20.29 (95% CI 3.28-∞, *p* \< 0.001), compared to the HIV-.

Infection with any of the 13 high-risk HPV subtypes showed a bivariate OR of 5.4 for GM (95% CI 2.01--15.03, *p* \<0.001) and 4.67 for TGW (95% CI 1.74--12.85, *p* \<0.001), compared to BM referents. The multivariate AOR for GM was 4.2 (95% CI 1.2--14.6, *p* = 0.021) and for TGW was 6.2 (95% CI 1.8--20.9, *p* = 0.003), compared to BM ([Table 7](#pone.0124499.t007){ref-type="table"}).

10.1371/journal.pone.0124499.t007

###### Crude and adjusted odds ratios by bivariate and logistic regression, for high-risk-type HPV positivity, by demographic, behavioral, and sexual risk factors of MSM in Chiang Mai, Thailand.
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  Characteristics                                                                        No. cases   Bivariate analysis   Logistic regression analysis                                                    
  -------------------------------------------------------------------------------------- ----------- -------------------- ------------------------------ ----------- --------------- -------- ----------- ---------------
  **Gender identity**                                                                                                                                                                                     
   Bisexual men                                                                          29          10 (35)              *Ref*.                                                     *Ref*.               
   Gay men                                                                               85          63 (74)              5.4                            2.0--15.0   ***0*.*000***   4.2      1.2--14.6   ***0*.*021***
   Transgender women                                                                     83          59 (71)              4.7                            1.7--12.8   ***0*.*000***   6.2      1.8--20.9   ***0*.*003***
  **HIV status**                                                                                                                                                                                          
   Negative                                                                              120         65 (54)              *Ref*.                                                     *Ref*.               
   Positive                                                                              48          45 (94)              12.7                           3.7--66.5   ***0*.*000***   12.8     3.6--45.8   ***0*.*000***
   Unknown                                                                               29          22 (76)              2.7                            1.0--7.9    ***0*.*033***   3.1      1.1--8.6    ***0*.*033***
  **Age in years**                                                                                                                                                                                        
   \< 20                                                                                 27          20 (74)              *Ref*.                                                                          
   20--29                                                                                108         67 (62)              0.6                            0.2--1.6    *0*.*243*                            
   30--39                                                                                47          32 (68)              0.8                            0.2--2.4    *0*.*587*                            
   40 or more                                                                            15          13 (87)              2.3                            0.4--25.3   *0*.*341*                            
  **Sexual role**                                                                                                                                                                                         
   Insertive only & both                                                                 78          47 (60)              *Ref*.                                                                          
   Receptive only                                                                        119         85 (71)              1.6                            0.9--3.2    *0*.*103*                            
  **Ever used hormones**                                                                                                                                                                                  
   Never                                                                                 98          61 (62)              *Ref*.                                                                          
   Ever                                                                                  99          71 (72)              1.5                            0.8--2.9    *0*.*157*                            
  **Alcohol consumption**                                                                                                                                                                                 
   Never                                                                                 18          14 (78)              *Ref*.                                                                          
   Ever                                                                                  179         118 (66)             0.6                            0.1--1.9    *0*.*308*                            
  **Frequency of sexual intercourse with BM, GM or TGM**                                                                                                                                                  
   1--2 times/week or less                                                               140         96 (69)              *Ref*.                                                                          
   3--4 times/week or more                                                               57          36 (63)              0.8                            0.4--1.6    *0*.*464*                            
  **Drank alcohol before having sex with BM, GM or TGW**                                                                                                                                                  
   Never / sometime                                                                      162         113 (70)             *Ref*.                                                     *Ref*.               
   Almost every time / Every time                                                        35          19 (54)              0.5                            0.2--1.2    *0*.*078*       0.6      0.2--1.4    *0*.*223*
  **Your BM, GM or TGW partner drank alcohol before having sex with you**                                                                                                                                 
   Never / sometime                                                                      164         111 (68)             *Ref*.                                                                          
   Almost every time / Every time                                                        33          21 (64)              0.8                            0.4--2.0    *0*.*652*                            
  **Ever received money, gifts or valuables in exchange for sex**                                                                                                                                         
   Never                                                                                 141         99 (70)              *Ref*.                                                                          
   Ever                                                                                  56          33 (59)              0.6                            0.3--1.2    *0*.*129*                            
  **Ever had any fluid, irritating urinary symptom, ulcer, or rash on your penis**                                                                                                                        
   No                                                                                    169         111 (66)             *Ref*.                                                                          
   Yes                                                                                   28          21 (75)              1.6                            0.6--4.6    *0*.*331*                            
  **Total sex partner(s) last 6 months**                                                                                                                                                                  
   0--1                                                                                  49          30 (61)              *Ref*.                                                                          
   2 or more                                                                             141         97 (69)              1.4                            0.7--2.9    *0*.*332*                            
  **Number of female sex partner(s) last 6 months**                                                                                                                                                       
   0--1                                                                                  172         120 (70)             *Ref*.                                                     *Ref*.               
   2 or more                                                                             16          6 (38)               0.3                            0.1--0.8    ***0*.*009***   0.8      0.2--3.7    *0*.*798*
  **Use condom all the time last 6 months with sex partner(s)**                                                                                                                                           
   No sex partner / No anal sex                                                          10          6 (60)               *Ref*.                                                                          
   Yes                                                                                   73          52 (71)              1.6                            0.3--7.8    *0*.*468*                            
   No                                                                                    107         69 (65)              1.2                            0.2--5.5    *0*.*777*                            
  **Use condom all the time last 6 months with** [**regular**]{.ul} **sex partner(s)**                                                                                                                    
   No sex partner / No anal sex                                                          74          52 (70)              *Ref*.                                                                          
   Yes                                                                                   46          30 (65)              0.8                            0.3--1.9    *0*.*563*                            
   No                                                                                    73          46 (63)              0.7                            0.3--1.5    *0*.*351*                            
  **Use condom all the time last 6 months with** [**casual**]{.ul} **sex partner(s)**                                                                                                                     
   No sex partner / No anal sex                                                          47          29 (62)              *Ref*.                                                                          
   Yes                                                                                   75          55 (73)              1.7                            0.7--4.0    *0*.*177*                            
   No                                                                                    72          47 (65)              1.2                            0.5--2.7    *0*.*691*                            

^**a**^ AOR = adjusted odd ratio. All measures adjusted for drinking alcohol before having sex and number of female sex partner(s) in last 6 months

OR = crude odds ratio

*Ref*. = Reference value.

For high-risk HPV subtypes, the HIV+ OR was 12.7 (95% CI 3.7--66.5, *p* \< 0.001) compared to HIV-. The high-risk AOR for HIV+ was 12.8 (95% CI 3.6--45.8, *p* \< 0.0001), compared to HIV-.

Discussion {#sec021}
==========

Our study showed an overall high prevalence of anal HPV infection with any of the 37 virus types assayed among northern Thai MSM who identified themselves as GM, BM, and TGW; and those who were HIV+ were 100% infected with HPV, significantly higher than those who were HIV- where the rate was 70%. This prevalence was higher than the 85% for HIV+ and 58.5% for HIV- MSM found in Bangkok in Central Thailand (nearly all were GM or BM), \[[@pone.0124499.ref010]\] as well as ever reported in other countries such as Brazil (65.6% for HIV+), \[[@pone.0124499.ref013]\] Taiwan (74.2% for HIV+), \[[@pone.0124499.ref014]\] and China (62--82% for HIV+, 58% for HIV-). \[[@pone.0124499.ref012],[@pone.0124499.ref015]\]

For the 13 HPV subtypes considered high risk for disease sequelae, our infection prevalence was also higher among HIV+ and HIV- participants (94% and 54%, respectively), compared to HIV+ and HIV- MSM from Bangkok, 56.5% and 36.6%, respectively \[[@pone.0124499.ref010]\] (this prior study reported overall MSM rates). Our most common high risk subtype found in HIV+ MSM was HPV16 followed by 58, 51, and 39, findings quite similar to Bangkok MSM, where the most common of all subtypes were HPV16 (22.5%), 68 (13.3%), 58 (10.8%), 51 (10.8%) and 39 (10%). \[[@pone.0124499.ref010]\] Our prevalence of high-risk HPV was also higher than reported from Brazil (40.7% for HIV+), \[[@pone.0124499.ref013]\] Taiwan (40.4% for HIV+), \[[@pone.0124499.ref014]\] and China (61% for HIV+, 40% for HIV-). \[[@pone.0124499.ref015]\]

Self-reported gender identity of GM and TGW was independently associated with prevalent HPV infection, when compared with BM, particularly for infection with high-risk HPV types. The prevalence was highest in those who self-identified as GM (74%) and TGW (71%) compared with those who self-identified as BM (35%). Others in Thailand and elsewhere described the prevalence of HPV infection in MSM, \[[@pone.0124499.ref010]--[@pone.0124499.ref015], [@pone.0124499.ref018], [@pone.0124499.ref019]\] but did not examine HPV epidemiology in gender-identity subpopulations that differ in sexual behavior practices. In particular, TGW were absent from published studies in Thai MSM. \[[@pone.0124499.ref018]\] We are unaware of others reporting our high overall and high-risk type HPV rates in TGW. Our study identified and confirmed previous findings that HIV+ is a stronger risk factor for overall and high-risk HPV infections than HIV- and HIV^unk^ status. \[[@pone.0124499.ref012]\]

The difference of vaccine coverage and ratio (above 2-valent) of the 9-valent HPV vaccine of any HIV statuses or gendered groups were higher than other vaccines. Although the 2-valent, 4-valent, and 7-valent HPV vaccines had lower coverage than the 9-valent, as would be expected, nevertheless these lesser-valent vaccines still had high coverage in the subjects we studied.

For HIV- participants, unprotected receptive anal intercourse was not associated with HPV, as was reported from Italy, \[[@pone.0124499.ref019]\] while, in contrast, this was significantly associated with HPV infection in China. \[[@pone.0124499.ref015]\] Our lack of multivariate association of HPV with increased numbers of sex partners differed from data in Italy in which both lifetime and recent numbers of sexual partners were significantly associated with anal HPV infection. \[[@pone.0124499.ref019]\] Drinking alcohol before sex also lacked any multivariate association among our participants. In contrast, the HIM study in São Paulo (Brazil), Cuernavaca (Mexico), and Tampa (USA) demonstrated alcoholic drinking in the past month was significantly associated with oncogenic HPV infection. \[[@pone.0124499.ref020], [@pone.0124499.ref021]\]

Our study had several advantages in studying anal HPV prevalence, including a large number of MSM who identify themselves specifically as GM, BM, and TGW. Little is known about HPV infection in TGW and its risk factors. Computer-assisted interviewing with CASI (see [methods](#sec006){ref-type="sec"}) may have reduced response bias as homosexual sex is still stigmatized in Thailand.

There were a number of limitations. The cross-sectional design did not allow evaluation of HPV incidence, causation, and progression, and may have been affected by confounding. The number of participants with and without confirmed HIV infection was small because of the unknown HIV status of many participants, which limited statistical sub-analyses. The limited number of HIV+ participants precluded evaluation of CD4 count and antiretroviral drug use, which have been found to be significantly associated with HPV infection in some studies. \[[@pone.0124499.ref022], [@pone.0124499.ref023]\] Our findings of vaccine coverage were only "partial", based on infection with one or more HPV types included in commercial and investigational vaccines. An analysis of "full" coverage of vaccines that would have prevented all the subtypes in patients infected with multiple types would have resulted in far lower coverage rates.

Our findings of HPV prevalence and vaccine coverage indicate that MSM in northern Thailand would benefit by protection from the serious consequences of HPV infection resulting from use of any of the HPV vaccines, with increasing protection as valences increases from 2 to 4 among commercial products, and from 7 to 9 among investigational ones. Further studies with follow-up of these and new consenting participants could evaluate in larger numbers the progression of HPV infection and its consequences.
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